Lewis Joseph's Form 4 filing
Tyra Biosciences, Inc. (TYRA) · filed Sep 17, 2021
- Accession no.
- 0000899243-21-036419
- Filed
- Sep 17, 2021, 4:38 PM ET
- Trade date
- Sep 17, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market purchases total $10.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis JosephCIK 0001015747 | 10% Owner |
| Boxer Asset Management Inc.CIK 0001465836 | 10% Owner |
| Boxer Capital, LLCCIK 0001465837 | 10% Owner |
| Davis Aaron I.CIK 0001465914 | 10% Owner |
| MVA Investors, LLCCIK 0001468223 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | CConversionAcquired | +5,698,359 | –F1 | – | 5,698,359 | Direct | |
| Sep 17, 2021 | Common Stock | PPurchaseAcquired | +625,000 | $16.00 | +$10,000,000 | 6,323,359 | Direct | |
| Sep 17, 2021 | Common Stock | CConversionAcquired | +288,095 | –F1 | – | 288,095 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | CConversionDisposed | −3,844,780 | $0.00 | $0 | 0 | Direct | Duplicate filing |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −248,093 | $0.00 | $0 | 0 | Direct | Duplicate filing |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −1,853,579 | $0.00 | $0 | 0 | Direct | Duplicate filing |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −40,002 | $0.00 | $0 | 0 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Referenced by the price of 2 transactions in Table I.